{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.31","upperLimit":"5.09","value":"2.05"},{"groupId":"OG001","lowerLimit":"0.99","upperLimit":"2.76","value":"1.31"},{"groupId":"OG002","lowerLimit":"1.35","upperLimit":"2.56","value":"1.45"},{"groupId":"OG003","lowerLimit":"1.25","upperLimit":"3.58","value":"3.02"},{"groupId":"OG004","lowerLimit":"1.28","upperLimit":"3.25","value":"2.12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"18"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of first dose to the date of first documentation of PD (including clinical progression or clinical deterioration) or death due to any cause, whichever occurs first. Per RECIST V1.1, PD was defined as at least a 20% increase in the sum of the LD of lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.","id":"OG000","title":"Western Safety Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG001","title":"Pancreatic Cancer Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.","id":"OG002","title":"Metastatic CRC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG003","title":"sqEC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.","id":"OG004","title":"sqNSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Set included all participants who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"From date of randomization until disease progression or death, whichever occurs first (Up to approximately 34 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}